RxDoctor Payments Data

Janie Yoo, MD

Ophthalmology · Lihue, HINPI 1932393170

Payments from drug & device makers

What this record shows

Alcon accounts for 69.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $2,434 and has fallen 85.1% since, to $362 in 2025.

$3,796in general payments, 2019–2025

Across 48 payments — averaging $79.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Sight Sciences, Inc.$524
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$129
  • Rxsight Inc$115
  • Johnson & Johnson Surgical Vision, Inc.$108
  • Glaukos Corporation$73
  • plus $209 from 5 others

What the payments were for

  • Travel & lodging$2,08855%
  • Food & beverage$1,70845%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,796 in reported general payments places this provider in the 60th percentile of 120 ophthalmology providers in Hawaii.

See all ophthalmology providers in Hawaii

Medicare billing

Part B allowed, 2024
$215,800
Medicare patients
515
Services billed
2,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast19$16,891
RestasisCyclosporine15$13,785
SimbrinzaBrinzolamide/Brimonidine Tart22$8,451
LumiganBimatoprost15$7,646
RhopressaNetarsudil Mesylate16$5,604
Latanoprost258$3,665
Brimonidine Tartrate71$2,425
Loteprednol Etabonate16$2,381
Prednisolone Acetate50$2,349
Dorzolamide Hcl29$726
ValacyclovirValacyclovir Hcl19$573
MoxifloxacinMoxifloxacin Hcl19$515
Timolol Maleate33$381
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat28$301
Ketorolac Tromethamine14$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AlconSimbrinza$2,638$8,45122 claims
Aerie Pharmaceuticals, Inc.Rhopressa$51$5,60416 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$129$2,38116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 120 ophthalmology providers in Hawaii.

Other ophthalmology in Lihue

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →